Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chere Cunjin Gao is a traditional Chinese medicine (TCM) formulation studied for the treatment of primary Sjögren's syndrome, specifically in patients with the TCM-defined pattern of yin deficiency and dryness-heat. It is being evaluated in multi-center clinical studies, including randomized double-blind trials, to assess its efficacy and safety for this indication. The precise herbal composition, mechanism of action at the molecular level, and pharmacological targets are not specified in available sources. Its use aligns with TCM principles rather than conventional Western pharmacology[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chere Cunjin Gao.